{"organizations": [], "uuid": "314a4d2a7f48203d0e256636e60fb2242a14150f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180110.html", "section_title": "Archive News &amp; Video for Wednesday, 10 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-glaukos-idose-travoprost-achieves/brief-glaukos-idose-travoprost-achieves-sustained-iop-reduction-and-favorable-safety-profile-in-12-month-interim-cohort-idUSFWN1P50GY", "country": "US", "domain_rank": 408, "title": "BRIEF-Glaukos' Idose Travoprost Achieves Sustained IOP Reduction And Favorable Safety Profile In 12-Month Interim Cohort", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.997, "site_type": "news", "published": "2018-01-10T20:10:00.000+02:00", "replies_count": 0, "uuid": "314a4d2a7f48203d0e256636e60fb2242a14150f"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-glaukos-idose-travoprost-achieves/brief-glaukos-idose-travoprost-achieves-sustained-iop-reduction-and-favorable-safety-profile-in-12-month-interim-cohort-idUSFWN1P50GY", "ord_in_thread": 0, "title": "BRIEF-Glaukos' Idose Travoprost Achieves Sustained IOP Reduction And Favorable Safety Profile In 12-Month Interim Cohort", "locations": [], "entities": {"persons": [], "locations": [{"name": "europe", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "glaukos corp", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 10 (Reuters) - Glaukos Corp:\n* GLAUKOS CORPORATION’S IDOSE™ TRAVOPROST ACHIEVES SUSTAINED IOP REDUCTION AND FAVORABLE SAFETY PROFILE IN 12-MONTH INTERIM COHORT\n* GLAUKOS CORP - COMPANY PREPARES TO COMMENCE PHASE III U.S. IND STUDY IN FIRST HALF OF 2018\n* GLAUKOS CORP - COMPANY BEGINS PROCESS FOR IDOSE TRAVOPROST REGULATORY APPROVAL IN EUROPE AND JAPAN\n* GLAUKOS CORP - CONDUCTED A PRODUCTIVE END-OF-PHASE II MEETING WITH FDA IN LATE 2017 ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-10T20:10:00.000+02:00", "crawled": "2018-01-11T12:34:02.017+02:00", "highlightTitle": ""}